March 31, 2025 12:23 PM EDTUpdated 02:06 PM

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

Elizabeth Cairns

Senior biopharma journalist

New data unveiled Monday showed that Merck’s Winrevair can significantly cut the risk of death, lung transplantation and hospitalization in patients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

New fund will pressure flailing biotechs, as investor frustration boils over

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

RFK Jr. touts CMS program testing new ways to pay for sickle cell disease treatment

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Mer­ck’s PAH drug cuts risk of se­ri­ous events by 76% in tri­al stopped for ef­fi­ca­cy

Senior biopharma journalist

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy